**Table S1. Baseline clinical characteristics of the patient**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Baseline | First HAIC＋TAE | Second HAIC＋TAE | Seven months after therapy |
| Age, year | 46 | - | - | - |
| Gender | Male | - | - | - |
| Family history | Father is diagnosed with liver cancer | | | |
| MAFLD | Absent | - | - | - |
| ALD | Absent | - | - | - |
| Cirrhosis | Absent | - | - | - |
| Child-Pugh score | 1 | 0 | 2 | 0 |
| HBsAg, IU/mL | 926.0 | 843.5 | 1653.4 | 800.6 |
| HBV DNA, IU/mL | 107000.0 | 12100.0 | 132.0 | 102.0 |
| AFP, ng/mL | 3836.0 | 1200.0 | 30.1 | 25.3 |
| AFP-L3, ng/mL | 1200.0 | 1200.0 | 6.8 | 4.1 |
| PIVKA-Ⅱ, ng/mL | 10730.0 | 1270.0 | 28.5 | 23.4 |
| ALT, U/L | 20.0 | 23.0 | 45.0 | 48.0 |
| AST, U/L | 35.0 | 38.0 | 35.0 | 36.0 |
| TBil, umol/L | 26.8 | 18.6 | 38.4 | 23.2 |
| ALB, g/L | 33.4 | 35.1 | 34.2 | 36.5 |
| GGT, U/L | 50.0 | 38.0 | 44.0 | 42.0 |
| RBC, × 1012/L | 5.4 | 6.0 | 5.6 | 5.3 |
| Hb, g/L | 111.0 | 123.0 | 119.0 | 125.0 |
| WBC, ×109/L | 7.9 | 5.3 | 3.9 | 5.1 |
| PLT, ×109/L | 403.0 | 194.0 | 93.0 | 103.0 |
| INR | 1.15 | 1.10 | 1.23 | 1.18 |
| TSH, uIU/mL | 1.7 | 5.3 | 1.6 | 1.6 |
| TT4, nmol/L | 121.1 | 97.7 | 90.0 | 100.1 |
| FT4, pmol/L | 17.9 | 12.5 | 12.4 | 13.5 |

AFP, alpha-fetoprotein; ALB, albumin; ALD, alcohol-related liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FT4, free thyroxine; GGT, gamma-glutamyl transferase; Hb, hemoglobin; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; INR, international normalized ratio; MAFLD, metabolic associated fatty liver disease; PIVKA-II, protein induced by vitamin K absence-II; PLT, platelet; RBC, red blood cell; TBil, total bilirubin; TSH, thyroid-stimulating hormone; TT4, total thyroxine; WBC, white blood cell.